ACRS
NASDAQ · Pharmaceuticals
Aclaris Therapeutics Inc
$5.91
-0.18 (-2.96%)
Financial Highlights (FY 2026)
Revenue
7.98M
Net Income
-66,186,376
Gross Margin
6.9%
Profit Margin
-829.6%
Rev Growth
-35.9%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 6.9% | 6.9% | 56.7% | 56.7% |
| Operating Margin | -975.9% | -878.3% | 17.2% | 20.4% |
| Profit Margin | -829.6% | -788.1% | 17.3% | 16.7% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 7.98M | 12.46M | 98.24M | 89.38M |
| Gross Profit | 553.3K | 863.6K | 55.74M | 50.72M |
| Operating Income | -77,920,050 | -109,455,353 | 16.92M | 18.22M |
| Net Income | -66,186,376 | -92,972,902 | 16.97M | 14.96M |
| Gross Margin | 6.9% | 6.9% | 56.7% | 56.7% |
| Operating Margin | -975.9% | -878.3% | 17.2% | 20.4% |
| Profit Margin | -829.6% | -788.1% | 17.3% | 16.7% |
| Rev Growth | -35.9% | -35.9% | +7.1% | +11.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 169.20M | 162.32M |
| Total Equity | — | — | 157.50M | 149.90M |
| D/E Ratio | — | — | 1.07 | 1.08 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -77,394,452 | -114,756,874 | 25.23M | 23.19M |
| Free Cash Flow | — | — | 16.84M | 23.02M |